Medical News

Study Findings on Nevirapine Support WHO HIV Treatment Guideline Changes

October 14, 2010

"Most HIV-positive women and children exposed to nevirapine (Viramune) during the peripartum period can go on to use the drug when they need highly active antiretroviral therapy (HAART) for their own health, researchers reported. But a significant minority will not respond to nevirapine-based treatment, even if they do not have resistance to the drug, according to two reports [here and here] in the Oct. 14 issue of the New England Journal of Medicine," MedPage Today reports (10/13). The authors of the second study write that both trials "strongly support the use of ritonavir-boosted lopinavir for the treatment of women and children who have had prior exposure to single-dose nevirapine" HealthDay News/ModernMedicine writes (10/13). The studies "helped influence the World Health Organization (WHO) to change its guidelines this year for the treatment of HIV infection in certain women and children," according to an NIH press release (10/13).

Back to other news for October 2010

This information was reprinted from with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.